Phase III SWOG-S0777 Trial of Bort/Len/Dex versus Len/Dex for Untreated MM without Intent for Immediate ASCT


Phase III SWOG-S0777 Trial of Bort/Len/Dex versus Len/Dex for Untreated MM without Intent for Immediate ASCT
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Noopur Raje, MD (2/10/16)
Durie B et al. Bortezomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): Results of the randomized phase III trial SWOG S0777. Proc ASH 2015;Abstract 25.

Dr Raje is Director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.